Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Aaron Kearsley
Institutions:
United States Department of Health and Human Services,
United States Food and Drug Administration,
Office of the Assistant Secretary for Planning and Evaluation
Observed institutions:
University of North Carolina at Chapel Hill,
United States Department of Health and Human Services,
United States Food and Drug Administration,
Office of the Assistant Secretary for Planning and Evaluation
ORCID:
0000-0001-5020-2266
Observed ORCID:
0000-0001-5020-2266
OpenAlex ID:
A5086635305
A further inquiry into the Pollution Haven Hypothesis and the Environmental Kuznets Curve
2009
·
Aaron Kearsley
, Mary Riddel
·
Ecological Economics
·
377
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey
2021
·
Allison R. Kolbe
, Aaron Kearsley
, et al.
·
BioDrugs
·
40
FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time
2024
·
Kathleen L. Miller
, Ariel D. Stern
, et al.
·
Health Affairs
·
5
PDF
Benefit–Cost Analysis of the HHS COVID-19 Campaign: April 2021–March 2022
2024
·
Sidney Turner
, Elissa C. Kranzler
, et al.
·
American Journal of Preventive Medicine
·
5
PDF
Willingness to pay to standardize patient medication information
2020
·
Bern Caudill Dealy
, Aaron Kearsley
, et al.
·
Applied Economics
·
3
A survey on perceived medication guide reading and comprehension ease among US adults
2024
·
Paul R Jones
, Jonas Santiago
, et al.
·
Health Promotion International
·
2
Measuring the Willingness-to-pay for standardizing medication information: a two-pronged stated preference approach
2023
·
Bern Caudill Dealy
, Carolyn Wolff
, et al.
·
Applied Economics
A Retrospective and Commentary on FDA’s Bar Code Rule
2018
·
Aaron Kearsley
, Nellie Lew
, et al.
·
Journal of Benefit-Cost Analysis
Show more works
View as search
Works count:
8
Citation count:
432
H-index:
4
I10-index:
2
Year
Topic
Type